immun
system
capabl
recogn
destroy
tumor
cell
brain
either
spontan
dope
immunotherapeut
strategi
decad
uncertainti
concern
tumor
immun
applic
cn
answer
twentyfirst
centuri
ye
number
caveat
best
summar
certain
condit
aim
chapter
overview
scienc
may
help
us
understand
particular
circumst
element
immun
system
recogn
destroy
tumor
brain
assess
inform
put
test
current
clinic
trial
dialogu
immun
system
brain
tumor
strongli
influenc
two
key
hypothes
immun
privileg
cancer
immunosurveil
origin
ago
medawar
report
allograft
cn
surviv
longer
tissu
medewar
led
barker
billingham
coin
term
immun
privileg
describ
site
barker
billingham
concept
limit
immun
respons
brain
interpret
consist
overrid
need
control
inflammatori
reaction
potenti
damag
consequ
neuron
network
low
regen
capac
absenc
lymphat
system
within
cn
presenc
special
bloodbrain
barrier
bbb
cn
compart
suggest
immun
isol
achiev
restrict
entri
bloodborn
molecul
immunoglobulin
well
leukocyt
albeit
mechan
constant
revis
bechmann
et
al
sever
decad
detail
observ
immun
respons
cn
clear
protect
eg
antivir
pathogen
eg
autoimmun
immun
respons
occur
cn
may
quantit
qualit
differ
occur
site
reapprais
cn
immun
privileg
bechmann
et
al
mani
compel
argument
made
redefinit
privileg
underlin
rel
state
applic
parenchyma
intact
noninflam
brain
moreov
perhap
view
longstand
oversimplist
interpret
immun
privileg
one
cornerston
modern
tumor
immunolog
cancer
immunosurveil
hypothesi
burnet
thoma
burnet
immedi
seen
directli
concern
brain
tumor
theori
propos
immun
system
continu
survey
organ
recogn
destroy
abnorm
cell
recognit
cancer
certainli
occur
clear
outcom
detect
alway
protect
immunosurveil
led
refin
theori
immunoedit
dunn
et
al
differ
outcom
describ
follow
cancer
immun
system
interact
name
elimin
equilibrium
tumor
escap
analysi
mous
model
clearli
defin
immunodefici
show
innat
adapt
immun
respons
influenc
tumor
outgrowth
mice
lack
lymphocyt
b
lymphocyt
natur
killer
nk
cell
defici
type
type
interferon
ifn
higher
tumor
incid
moreov
analys
larg
cohort
immunosuppress
patient
show
incid
viral
associ
cancer
also
cancer
known
associ
infect
increas
howev
date
brain
tumor
among
tumor
note
occur
frequent
like
due
lower
expect
frequenc
malign
may
also
brain
tumor
rare
elimin
spontan
like
persist
equilibrium
host
els
rapidli
escap
immun
control
would
appear
case
malign
glioma
detect
case
notion
immunoedit
predict
outgrow
tumor
sculpt
interact
immun
system
exampl
select
tumor
abl
neutral
immun
effector
mechan
discuss
see
note
idea
context
spontan
immun
spontan
cancer
occur
studi
inde
natur
occur
immun
mechan
endow
millennia
select
evolut
may
provid
preciou
inform
ration
immunotherapi
design
first
step
tumor
immun
alert
immun
system
presenc
tumor
achiev
innat
immun
innat
immun
system
compris
solubl
factor
compon
complement
system
import
tumor
immun
cell
macrophagesmicroglia
granulocyt
nk
cell
dendrit
cell
dc
cell
effici
detect
pathogenassoci
molecular
pattern
mean
germlineencod
pathogenrecognit
receptor
prr
includ
tolllik
receptor
tlr
howev
role
understood
wider
mere
detect
infect
pathogen
also
detect
perturb
organ
consid
danger
matzing
prr
also
view
pattern
recognit
receptor
abl
deliv
danger
signal
exampl
endogen
ligand
identifi
human
tlr
except
tlr
includ
heat
shock
protein
hsp
upregul
stress
cell
bind
tlr
nucleic
acid
releas
die
tumor
cell
bind
tlr
barrat
coffman
barton
medzhitov
pulendran
detect
cancer
initi
mediat
tissueresid
sentinel
cell
innat
immun
system
tissu
dc
macrophag
brain
dc
resid
parenchyma
although
may
appear
later
stage
respons
import
endogen
sentinel
microgli
cell
hanisch
kettenmann
special
brain
macrophag
wide
distribut
throughout
brain
parenchyma
may
actual
recruit
site
glioma
occurr
repres
third
cell
compos
tumor
graeber
et
al
microglia
express
sever
tlr
includ
tlr
propos
bind
sever
factor
produc
die
cell
glioma
microenviron
hussain
et
al
tlr
ligat
lead
full
activ
microgli
cell
subsequ
function
potenti
includ
phagocytosi
chemokin
cytokin
releas
antigen
present
even
tumor
cell
kill
howev
less
use
outcom
suggest
includ
neurotox
enhanc
tumor
invas
upregul
metalloproteinas
contrast
function
may
attribut
extrem
plastic
microglia
respons
local
milieu
inde
brain
microenviron
must
function
also
compris
astrogli
cell
exhibit
characterist
innat
immun
function
includ
prr
express
activ
reactiv
state
secret
cytokin
chemokin
farina
et
al
furthermor
case
malign
microgli
function
also
subject
modul
local
tumor
microenviron
hussain
et
al
markov
et
al
protect
antitumor
immun
respons
endogen
sentinel
innat
immun
alert
two
subsequ
event
limit
elimin
sourc
danger
innat
effector
function
resid
cell
recruit
resourc
particularli
cell
discuss
next
section
glioma
littl
vivo
evid
suggest
tumoricid
microglia
spontan
restrain
brain
tumor
growth
graeber
et
al
innat
effector
cell
potenti
recogn
kill
tumor
cell
nk
cell
subject
intens
investig
character
receptor
regul
function
order
mediat
cytolysi
nk
cell
must
receiv
signal
one
activ
receptor
result
activ
must
absenc
signal
inhibitori
receptor
eg
member
famili
receptor
lanier
express
ligand
low
normal
cell
upregul
cell
subject
genotox
stress
occur
neoplast
transform
inde
certain
human
glioma
fulfil
requir
nk
cell
recognit
activ
express
ligand
micab
major
histocompat
complex
mhc
class
ichainrel
molecul
b
protein
ulbp
eisel
et
al
downregul
hla
molecul
ligand
inhibitori
receptor
facoetti
et
al
nk
cell
cytotox
also
earli
sourc
angiostat
amplifi
tcell
mediat
tumor
immun
howev
littl
known
nk
cell
potenti
impact
tumor
site
human
glioma
although
murin
intracrani
tumor
model
melanoma
interact
dc
nk
cell
cell
facilit
protect
tumor
immun
prin
et
al
cell
matur
ie
cell
yet
stimul
cognat
antigen
gener
thymu
travel
blood
lymph
recircul
secondari
lymphoid
organ
spleen
ln
although
major
cell
effici
enter
nonlymphoid
tissu
includ
cn
except
report
brabb
et
al
atyp
tcell
traffick
probabl
account
signific
proport
cell
normal
condit
may
even
associ
toler
induct
rather
induct
effici
antitumor
immun
therefor
understand
gener
efficaci
tumor
immun
convent
traffick
activ
cell
ln
consid
larg
number
cell
gener
individu
bear
clonal
distribut
antigen
receptor
gener
somat
rearrang
limit
number
gene
segment
encod
heterodimer
tcell
receptor
antigen
tcr
compris
chain
main
tcell
popul
discuss
chain
receptor
use
minor
tcell
popul
ligand
tcr
cell
short
peptid
around
amino
acid
bound
class
mhc
molecul
wherea
cell
recogn
slightli
longer
peptid
amino
acid
bound
mhc
class
ii
molecul
sinc
tcr
randomli
gener
repertoir
potenti
includ
receptor
conceiv
specif
frequenc
cell
express
tcr
given
specif
whole
cell
popul
low
order
cell
necessit
signific
clonal
expans
order
cell
achiev
biolog
effect
vivo
cell
receiv
singl
signal
via
ligat
tcr
mhcpeptid
complex
may
becom
anerg
ie
without
effector
function
refractori
stimul
full
activ
cell
becom
effector
cell
requir
second
signal
usual
deliv
costimulatori
molecul
member
famili
particularli
express
antigen
present
cell
apc
innat
immun
system
effici
dc
fig
activ
cell
prime
apc
within
secondari
lymphoid
tissu
trigger
clonal
expans
cell
differenti
program
influenc
magnitud
qualiti
antitumor
immun
respons
ie
tcell
effector
function
cytotox
cytokin
releas
suppress
tissu
tropism
persist
effector
memori
cell
although
occur
ln
factor
princip
predetermin
innat
immun
reaction
upstream
tumor
site
vaccin
site
result
clonal
expand
cell
highli
enrich
tumor
antigen
specif
exit
ln
via
effer
lymph
enter
bloodstream
traffic
less
effici
tumor
site
depend
upon
pattern
adhes
molecul
chemokin
receptor
home
phenotyp
program
express
dc
best
understood
rout
antigen
transport
ln
via
dc
abl
phagocytos
tumorderiv
antigen
migrat
via
lymphat
vessel
tcell
zone
drain
ln
wherein
await
encount
recircul
cell
specif
captur
antigen
bound
mhc
molecul
brain
tumor
scenario
complic
particular
cn
cellular
composit
anatomi
lymphat
vessel
brain
resid
dc
healthi
brain
parenchyma
nevertheless
sever
differ
experiment
approach
confirm
function
antigen
drainag
brain
parenchyma
lymphoid
tissu
occur
princip
cervic
ln
cserr
knopf
earli
studi
examin
transport
solubl
product
flow
interstiti
tissu
fluid
via
perivascular
space
drain
either
subarachnoid
space
lymphat
via
arachnoid
sheath
certain
cranial
nerv
spinal
nerv
root
reach
cervic
ln
bechmann
et
al
recent
particul
materi
also
shown
reach
cervic
submandibular
ln
intracerebr
inject
walter
albert
studi
confirm
function
drainag
absenc
lymphat
adequ
explain
initi
adapt
immun
occur
without
induct
immun
toler
must
antigen
present
cell
cervic
ln
also
second
signal
indic
danger
infect
best
understood
sourc
second
signal
apc
sens
danger
sourc
ie
tumor
site
brain
cell
abl
transport
brain
tumorderiv
antigen
materi
ln
stimul
cell
therein
follow
properti
phagocyt
abl
process
present
tumor
antigen
mhc
class
class
ii
molecul
express
costimulatori
molecul
migratori
microglia
abund
phagocyt
brain
induc
express
costimulatori
molecul
present
antigen
mhc
class
ii
restrict
cell
vitro
aloisi
et
al
demand
function
crosspresent
ie
uptak
exogen
antigen
present
process
peptid
deriv
therefrom
mhc
class
molecul
report
one
vitro
studi
use
ovalbumin
antigen
beauvillain
et
al
whether
vitro
result
appli
microglia
vivo
debat
partli
criteria
use
defin
microglia
morpholog
anatom
locat
level
express
macrophag
associ
marker
even
function
davoust
et
al
inde
effici
antigen
present
vitro
requir
phenotyp
function
reactiv
activ
microgli
cell
virtual
indistinguish
activ
macrophag
final
function
necessari
vivo
initi
tcell
immun
migrat
ln
express
chemokin
receptor
associ
migrat
ln
report
murin
microglia
dijkstra
et
al
function
ln
home
experi
perform
vivo
studi
suggest
brain
apc
function
present
peptid
cell
resid
popul
perivascular
cell
origin
character
radiosensit
platten
steinman
fact
cell
may
repres
differenti
microglia
express
dc
marker
morpholog
resembl
dc
fischer
reichmann
howev
phenotyp
studi
alway
allow
extrapol
function
differ
mous
model
cn
dc
interact
cell
defin
either
stimulatori
fischer
reichmann
ling
et
al
inhibitori
suter
et
al
overal
studi
confirm
plastic
microgli
cell
may
give
rise
cell
resembl
macrophag
dc
give
definit
answer
origin
ident
cell
ultim
abl
form
link
innat
immun
detect
malign
brain
induct
adapt
immun
ln
could
still
convent
dc
precursor
recruit
either
peripher
brain
region
rich
cell
choroid
plexu
mening
venou
blood
respons
initi
microgli
astrogli
activ
altern
approach
address
issu
cn
ln
apc
migrat
inject
label
dc
brain
track
subsequ
migrat
approach
case
confirm
migrat
cervic
ln
carson
et
al
ehtesham
et
al
karman
et
al
kuwashima
et
al
although
may
limit
interpret
system
first
migratori
behavior
inject
dc
may
accur
reflect
endogen
pathway
second
volum
site
inject
within
cn
brain
parenchyma
vs
ventricl
may
influenc
migrat
pattern
bechmann
et
al
hatter
et
al
thoma
et
al
howev
despit
consider
tcell
activ
expans
observ
cervic
ln
brain
tumor
model
reliant
endogen
apc
calzascia
et
al
prin
et
al
walter
albert
report
suggest
principl
factor
influenc
entri
cell
brain
activ
differenti
statu
cell
activ
statu
vasculatur
nevertheless
antigenspecif
compon
tcell
recruit
brain
propos
studi
peptid
inject
intracerebr
subsequ
present
lumin
surfac
endotheli
cell
galea
et
al
howev
current
unclear
whether
endotheli
cell
would
effici
phagocytos
crosspres
tumorderiv
antigen
present
solubl
peptid
remain
determin
whether
mechan
relev
tumor
immun
gener
consid
opportun
cell
interact
specif
antigen
travers
endothelium
barrier
demonstr
preferenti
retent
brain
autoreact
virusspecif
cell
hickey
tumor
specif
cell
calzascia
et
al
gener
featur
leukocyt
extravas
common
tissu
similar
hemodynam
constraint
enorm
veloc
cell
bloodstream
rel
static
endotheli
cell
form
vessel
structur
initi
reduc
transient
adhes
interact
cell
endothelium
selectin
eg
eselectin
pselectin
endothelium
engag
ligand
cell
slow
flow
cell
begin
roll
along
vessel
wall
facilit
contact
chemokin
receptor
cell
correspond
immobil
chemokin
lumin
face
endotheli
cell
chemokin
receptor
signal
lead
conform
chang
tcellexpress
integrin
allow
firm
adhes
cell
adhes
molecul
endothelium
arrest
diapedesi
butcher
et
al
tissuespecif
combin
adhes
molecul
chemokin
allow
select
recruit
particular
tcell
popul
luster
et
al
mani
underli
concept
immun
cell
entri
cn
base
cn
autoimmun
condit
princip
multipl
sclerosi
ms
patient
experiment
autoimmun
encephalomyel
eae
mice
engelhardt
preciou
inform
may
also
appli
cerebr
malign
requir
valid
inde
preponder
inform
cell
eae
less
cell
furthermor
certain
molecular
consider
home
propos
influenc
mous
strain
precis
cn
region
factor
yet
address
tumor
nevertheless
sever
key
find
appear
appli
differ
strain
speci
neuropatholog
tabl
adhes
molecul
consist
implic
tcell
entri
cn
speci
model
test
integrin
integrin
express
heterodim
partner
either
integrin
chain
cn
integrin
also
call
interact
endotheli
cell
central
eae
may
facilit
lower
affin
roll
interact
higher
affin
arrest
accord
particular
cn
microvasculatur
involv
engelhardt
mous
brain
tumor
model
integrin
also
shown
key
molecul
tcell
entri
tumor
site
found
high
level
integrin
induc
tumorspecif
cell
prw
pyd
unpublish
data
cell
calzascia
et
al
prime
endogen
apc
cervic
ln
brain
tumorbear
mice
function
relev
sinc
block
antibodi
significantli
reduc
brain
entri
cell
explor
role
integrin
brain
tropism
perform
cell
polar
toward
differ
cytokinesecret
profil
mous
cell
type
profil
express
higher
level
integrin
traffick
brain
effici
type
interleukin
il
secret
cell
sasaki
et
al
find
particularli
relev
brain
tumor
immunotherapi
sinc
cell
receiv
vitro
vivo
stimuli
manifest
two
key
characterist
efficaci
antitumor
function
appropri
tissu
tropism
cytokin
express
key
integrin
also
implic
cn
entri
cell
human
patient
ms
receiv
novel
treatment
integrin
target
use
human
antibodi
natalizumab
reduc
level
inflammatori
leukocyt
cerebrospin
fluid
gener
show
clinic
improv
stuve
et
al
taken
togeth
result
differ
studi
unequivoc
establish
import
role
integrin
tcell
home
cn
howev
interpret
mean
specif
target
cell
brain
sinc
studi
analyz
singl
tissu
brain
rather
like
integrin
abundantli
express
cell
molecul
facilit
entri
cn
nevertheless
sinc
inhibit
block
total
abrog
cell
entri
cn
molecul
probabl
also
involv
may
either
substitut
synerg
date
mix
find
involv
nonintegrin
adhes
molecul
tcell
entri
cn
nearli
data
deriv
studi
eae
ms
find
often
specif
particular
cn
region
specif
stage
diseas
role
tcell
extravas
brain
tumor
either
spontan
immun
immunotherapi
applic
exclud
induct
e
pselectin
ligand
tumorspecif
cell
divid
cervic
ln
observ
mice
harbor
intracrani
tumor
function
signific
observ
analyz
calzascia
et
al
pselectin
lesser
extent
eselectin
ligand
found
contribut
tcell
roll
certain
inflam
cn
microvessel
use
intravit
microscopi
vitro
studi
studi
conclud
cell
ms
patient
preferenti
roll
via
pselectin
wherea
cell
roll
via
integrin
battistini
et
al
howev
other
found
cn
inflamm
alter
follow
genet
ablat
overexpress
e
pselectin
ligand
antibodi
block
engelhardt
therefor
real
vivo
signific
selectin
least
eae
difficult
establish
adhes
molecul
may
influenc
tcell
adhes
endothelium
lymphocyt
functionassoci
express
activ
cell
intercellular
adhes
molecul
ligand
present
either
constitut
activ
cn
microvessel
includ
human
glioma
engelhardt
kuppner
et
al
vitro
studi
eae
suggest
potenti
role
particularli
transendotheli
migrat
cell
vivo
experi
difficult
interpret
probabl
icam
interact
also
critic
immunolog
synaps
facilit
antigenspecif
interact
cell
apc
target
cell
recent
observ
highlight
role
activ
leukocyt
cell
adhes
molecul
alcam
facilit
cn
infiltr
cell
monocyt
cayrol
et
al
express
alcam
note
higher
bbb
endotheli
cell
endothelium
organ
upregul
inflam
vasculatur
antibodi
blockad
experi
show
cell
monocyt
transmigr
across
brain
endotheli
cell
partial
alcam
depend
alcam
neutral
vivo
reduc
eae
sever
noteworthi
among
cell
tcell
subset
appear
use
alcam
transmigr
sinc
cell
total
unaffect
even
though
express
similar
level
alcam
receptor
find
confirm
context
brain
tumor
immun
may
open
futur
possibl
modul
tcell
subset
brain
infiltr
futur
immunotherapi
chemokin
low
molecular
weight
chemoattract
cytokin
function
bind
gprotein
coupl
receptor
express
wide
rang
cell
includ
leukocyt
unravel
role
individu
chemokin
receptor
complex
chemokin
bind
multipl
receptor
receptor
bind
multipl
chemokin
furthermor
context
brain
tumor
tumor
sourc
chemokin
may
influenc
quantiti
qualiti
result
immun
infiltr
van
meir
dey
et
al
brown
et
al
jordan
et
al
chemokin
propos
influenc
multipl
step
cn
infiltr
blood
migrat
within
brain
parenchyma
although
step
valid
vivo
cn
rebenkomol
et
al
lumen
cn
microvessel
chemokin
immobil
endotheli
cell
trigger
integrin
activ
tether
leukocyt
particularli
context
brain
tropic
cell
facilit
highaffin
interact
arrest
diapedesi
promot
chemokin
mediat
locomot
interendotheli
junction
cell
may
sampl
ablumin
chemokin
extend
process
intercellular
junction
final
chemokin
gradient
exist
within
brain
parenchyma
attract
cell
tumor
site
concern
role
specif
chemokin
tcell
infiltr
brain
tumor
vivo
studi
perform
conclus
mostli
base
eae
ms
infect
neurotrop
virus
rebenkomol
et
al
proport
cell
express
enhanc
among
cell
present
cerebrospin
fluid
patient
ms
eae
level
two
ligand
elev
csf
acut
phase
ms
howev
vivo
experi
block
antibodi
defici
mice
yield
conflict
result
probabl
influenc
eae
multipl
level
eg
product
level
traffick
similar
consider
exist
ligand
suggest
role
cn
viral
infect
includ
west
nile
viru
hiv
coronaviru
probabl
relat
tcell
function
rather
traffick
anoth
chemokin
receptor
express
cell
ligand
may
multipl
role
cn
patholog
cerebrospin
fluid
patient
ms
brain
lesion
mice
progress
eae
accumul
cell
moreov
addit
two
ligand
express
bbb
brain
mice
eae
least
vitro
mediat
adhes
cell
howev
studi
vivo
function
signific
difficult
use
block
antibodi
gene
defici
mice
sinc
cell
subset
memori
cell
tcm
well
dc
express
previou
section
indic
littl
direct
data
properti
protect
cell
abl
traffic
effici
brain
tumor
nevertheless
level
infiltr
tumorspecif
cell
factor
limit
efficaci
immunotherapi
mani
current
tumor
tcell
immunotherapi
protocol
adapt
directli
therapi
test
tumor
site
yet
tumor
patholog
fundament
differ
lethal
extracrani
tumor
due
metastas
goal
tcell
immunotherapi
therapeut
cell
reach
mani
site
tumor
dissemin
primari
cn
malign
malign
glioma
situat
differ
tumor
uniqu
oncolog
rare
metastas
tissu
origin
immunolog
problem
tumor
thu
strictli
one
region
immun
thu
promot
effici
brain
tropism
protect
immun
cell
undoubtedli
benefit
futur
glioma
immunotherapi
necessari
understand
induc
key
molecul
cellentri
cn
also
avoid
induct
home
phenotyp
may
lead
entrap
elsewher
exampl
mucos
surfac
high
express
regard
preclin
model
multipl
site
studi
help
calzascia
et
al
emerg
technolog
whole
bodi
imag
particularli
appropri
prin
et
al
refin
would
ensur
infiltr
protect
cell
sinc
gross
augment
inflammatori
infiltr
inappropri
danger
brain
understand
subsetspecif
traffick
achiev
would
use
object
optim
therapi
ideal
antitumor
immun
respons
tumorspecif
cytotox
lymphocyt
ctl
penetr
brain
parenchyma
made
contact
tumor
kill
malign
cell
direct
cellmedi
cytotox
occur
preclin
brain
tumor
model
date
possibl
minor
malign
cell
form
intracrani
tumor
mass
patient
glioma
cell
fulli
activ
peripheri
tumor
cell
need
express
mhc
class
ipeptid
costimulatori
molecul
essenti
effector
stage
becom
ctl
target
cytotox
occur
polar
exocytosi
content
cytotox
granul
immunolog
synaps
form
ctl
tumor
target
exquisit
specif
bystand
kill
granul
content
includ
perforin
granulysin
perturb
tumor
cell
membran
serin
proteas
known
granzym
induc
tumor
cell
death
mainli
caspasedepend
pathway
secondari
cytotox
mechan
also
exist
cellassoci
cellsecret
cytotox
molecul
includ
fa
ligand
tumor
necrosi
factor
tnf
lymphotoxin
lt
antitumor
effect
also
mediat
cell
indirect
recognit
tumor
deriv
antigen
peptid
mhc
class
molecul
apc
ie
crosspresent
alreadi
discuss
role
apc
prime
tcell
respons
ln
essenti
may
also
role
effector
stage
respons
inde
local
apc
potenti
amplifi
tcellmedi
antitumor
effect
occur
low
level
direct
celltumor
cell
contact
karman
et
al
masson
et
al
may
substitut
contact
absenc
direct
antigen
present
tumor
cell
exampl
mhc
downregul
one
key
factor
propos
indirect
antitumor
effect
imped
tumor
growth
act
receptor
express
tumor
stroma
inhibit
angiogenesi
qin
et
al
crosspresent
antigen
cell
demonstr
vitro
microgli
cell
beauvillain
et
al
principl
crosspres
apc
vivo
like
dc
jung
et
al
crosspres
dc
brain
yet
report
knowledg
human
malign
glioma
one
consequ
crosspresent
antigen
antigenspecif
cell
retain
site
cellular
interact
inde
observ
retent
tumorspecif
cell
brain
mous
model
design
address
issu
crosspresent
calzascia
et
al
model
intracrani
implant
astrocytoma
cell
unabl
directli
present
defin
tumor
antigen
present
tumor
antigen
cell
brain
occur
sole
crosspresent
although
ident
apc
studi
determin
sever
experiment
situat
indirect
stimul
cell
tumor
site
achiev
intracrani
inject
dc
ehtesham
et
al
kikuchi
et
al
masson
et
al
nishimura
et
al
pellegatta
et
al
local
function
cell
may
enhanc
tcell
prolifer
tumor
site
promot
tcell
retent
brain
andor
amplifi
effector
function
releas
role
cell
brain
tumor
immun
complex
cell
differenti
toward
least
four
differ
subset
treg
difficult
identifi
phenotyp
either
pro
antitumor
effect
moreov
glioma
antigen
recogn
cell
identifi
nevertheless
assum
cell
compon
brain
tumor
immun
may
antitumor
activ
potenti
aid
tcell
accumul
surviv
function
demonstr
certain
rodent
model
ciesielski
et
al
wang
et
al
glioma
may
attempt
passiv
escap
immun
detect
downregul
mhc
express
molecul
associ
antigen
present
cell
interestingli
characterist
associ
higher
grade
astrocytoma
facoetti
et
al
mehl
et
al
import
futur
immunotherapi
strategi
vitro
observ
mhc
upregul
glioblastoma
cell
line
yang
et
al
tumor
cell
escap
tcell
mediat
immun
downregul
mhc
express
may
risk
attack
nk
cell
normal
inact
inhibitori
receptor
ligat
mhc
howev
sever
adapt
malign
glioma
may
guard
express
mica
ligand
nkgd
activ
receptor
nk
cell
low
absent
grade
iii
iv
astrocytoma
eisel
et
al
wherea
array
ligand
hlae
hlag
lectinlik
inhibitori
nk
receptor
overexpress
roth
et
al
wischhusen
et
al
major
consider
consid
factor
lead
immun
escap
presenc
area
hypoxia
well
document
human
glioma
loui
area
tumor
particularli
hostil
microenviron
immun
cell
function
surviv
cell
may
particularli
sensit
low
oxygen
tension
sitkovski
lukashev
solubl
factor
act
either
directli
effector
cell
recruit
third
parti
immunosuppress
cell
case
molecul
may
function
multipl
way
notori
exampl
multifunct
cytokin
directli
suppress
nk
tcell
prolifer
antitumor
function
includ
granzym
fasl
express
also
promot
suppress
cell
see
angiogenesi
tumor
invas
wrzesinski
et
al
particular
isoform
produc
glioma
cell
line
glioblastoma
vivo
bodmer
et
al
liau
et
al
moreov
phase
dc
vaccin
trial
glioblastoma
note
increas
intratumor
infiltr
ctl
four
eight
patient
underw
reoper
vaccin
invers
correl
express
within
tumor
posit
correl
clinic
surviv
p
liau
et
al
consequ
effect
becom
attract
target
novel
therapeut
approach
inhibitor
antisens
oligonucleotid
activ
explor
solubl
factor
astrocytoma
origin
may
immunosuppress
potenti
includ
prostaglandin
gangliosid
walker
et
al
real
vivo
concentr
impact
factor
yet
firmli
establish
candid
immunosuppress
molecul
fa
ligand
involv
immun
homeostasi
cytotox
induc
apoptosi
target
cell
glioma
express
fa
ligand
vitro
vivo
vitro
fa
ligand
express
glioma
cell
line
kill
fa
express
cell
line
autolog
donor
vivo
role
fa
ligand
express
tumor
cell
controversi
walker
et
al
glioma
also
express
also
call
member
famili
abl
interact
tcell
express
program
receptor
express
cell
wilmott
et
al
wintterl
et
al
interact
neg
regul
tcell
activ
interestingli
express
associ
genet
event
glioma
loss
tumor
suppressor
pten
activ
kinas
pathway
parsa
et
al
immunosuppress
potenti
interact
vivo
yet
explor
intracrani
tumor
anoth
cell
surfac
molecul
propos
facilit
glioma
immun
escap
engag
counterreceptor
immun
cell
induc
apoptosi
express
glioma
vitro
inde
trigger
apoptosi
immun
cell
review
walker
et
al
howev
first
vivo
studi
glioma
transfect
indic
immun
stimulatori
role
author
even
suggest
exploit
axi
immunotherapi
aulwurm
et
al
role
express
nonmanipul
human
glioma
vivo
therefor
await
clarif
recent
year
major
resurg
interest
understand
cellularbas
mechan
may
regul
suppress
tumor
immun
cell
differ
origin
see
involv
suppress
immun
respons
valuabl
role
regul
autimmmun
control
inflamm
howev
function
may
also
blunt
spontan
vaccineinduc
tumor
immun
furthermor
immunosuppress
cell
case
recruit
induc
factor
eg
cytokin
produc
tumor
cell
mesenchym
stem
cell
strong
antiinflammatori
antiprolif
effect
immun
cell
may
increas
glioma
cell
prolifer
attract
glioma
cultur
supernat
purifi
factor
includ
vegf
birnbaum
et
al
vivo
immunosuppress
role
glioma
remain
determin
myeloidderiv
suppressor
cell
anoth
potenti
immunosuppress
cell
type
receiv
increas
attent
context
cancer
noteworthi
stimul
prostaglandin
secret
glioma
cell
marx
myeloidderiv
suppressor
cell
also
studi
context
brain
tumor
model
prin
et
al
although
littl
known
presenc
brain
tumor
site
patient
cellular
mediat
immun
suppress
current
studi
cancer
regulatori
cell
treg
bestdefin
suppressor
cell
sakaguchi
et
al
either
treg
produc
function
matur
tcell
subset
thymu
natur
treg
cell
differenti
induc
treg
influenc
certain
cytokin
includ
role
treg
immun
homeostasi
well
defin
maintain
immunolog
toler
selfantigen
mutat
lead
absenc
anim
scurfi
mice
patient
ipex
inhibit
ablat
lead
autoimmun
inflammatori
diseas
treg
function
array
cell
contact
cytokinemedi
mechan
suppress
cell
b
cell
nk
cell
macrophag
dc
induct
effector
stage
immun
respons
context
malign
treg
accumul
mani
tumor
includ
human
glioma
el
andaloussi
lesniak
fecci
et
al
hussain
et
al
treg
deplet
inhibit
murin
brain
tumor
model
reveal
spontan
tumor
immun
enhanc
induc
immun
curtin
et
al
el
andaloussi
et
al
fecci
et
al
grauer
et
al
import
treg
antiglioma
immun
respons
wide
accept
mani
challeng
identifi
modul
cell
foremost
lack
uniqu
marker
identifi
treg
marker
share
activ
effector
cell
eg
best
specif
treg
marker
mice
transcript
factor
intracellular
inaccess
antibodi
vivo
express
restrict
treg
human
cell
signific
progress
defin
natur
antitumor
respons
made
discoveri
character
taa
begin
report
first
melanoma
antigen
mage
van
den
eynd
et
al
van
der
bruggen
et
al
intens
research
underway
use
taa
potenti
target
immunebas
cancer
treatment
key
taa
investig
tyrosinas
melanoma
panelli
et
al
parkhurst
et
al
riba
riba
et
al
psa
pap
prostat
cancer
murphi
et
al
survivin
mani
solid
tumor
katoh
et
al
breast
ovarian
cancer
disi
et
al
knutson
disi
knutson
et
al
promin
issu
distinguish
cerebr
malign
tumor
melanoma
pauciti
welldefin
tumorspecif
antigen
inde
difficulti
immun
respons
monitor
particularli
acut
patient
malign
glioma
contrast
patient
melanoma
extens
character
tumor
antigen
recogn
cell
unless
advanc
domain
occur
ration
advanc
immunebas
brain
tumor
therapi
may
significantli
hamper
recent
year
genomewid
techniqu
dramat
acceler
abil
obtain
molecular
profil
gene
defect
glioma
result
readili
access
sourc
inform
gene
gene
product
produc
antigen
tcga
advanc
brain
tumor
immunom
led
recent
identif
sever
taa
express
human
glioma
includ
tumorspecif
antigen
uniqu
oncogen
transform
process
egfrviii
overexpress
follow
activ
oncogen
pathway
husain
et
al
kuwashima
et
al
okano
et
al
saikali
et
al
shimato
et
al
wu
et
al
see
also
chapter
cancertest
antigen
normal
express
develop
cancertest
antigen
mage
gage
sart
ssx
bodey
et
al
chi
et
al
sahin
et
al
neuroectoderm
antigen
involv
pigment
synthesi
eg
melanomaassoci
antigen
tyrosinas
liu
et
al
b
saikali
et
al
zhang
et
al
antigen
associ
prolifer
cell
surviv
htert
survivin
bcyclin
katoh
et
al
liu
et
al
saikali
et
al
ueda
et
al
zhang
et
al
recent
studi
addit
suggest
mani
human
glioma
latent
infect
human
cytomegaloviru
cmv
cobb
et
al
mitchel
et
al
cmv
may
clinic
relev
target
immunebas
therapi
prin
et
al
mani
taa
origin
identifi
via
serolog
analysi
tumor
antigen
recombin
cdna
express
clone
serex
immunogen
solid
tumor
melanoma
chen
et
al
similar
attempt
identifi
antigen
recogn
immun
system
rat
glioma
immun
success
identifi
mous
idassoci
protein
mida
antigen
could
induc
antitumor
immun
okada
et
al
human
glioma
howev
attempt
identifi
tcell
antigen
less
success
pallasch
et
al
schmit
et
al
nevertheless
recent
studi
demonstr
mani
establish
human
glioma
cell
line
express
wellcharacter
taa
recogn
antigenspecif
cell
zhang
et
al
interestingli
pattern
antigen
express
seem
differ
adult
pediatr
human
glioma
okada
et
al
zhang
et
al
rapid
advanc
provid
high
throughput
microarray
chip
technolog
entir
compendium
gene
show
elev
express
tumor
soon
establish
repertoir
potenti
gliomaspecif
antigen
defin
horvath
et
al
liau
et
al
mischel
et
al
b
furthermor
recent
progress
understand
tumor
immunolog
link
inform
gener
geneexpress
profil
cn
tumor
identif
precis
immunogen
epitop
serv
use
target
specif
immunotherapi
freij
et
al
instanc
sinc
cell
recogn
antigen
context
mhc
tumorassoci
gene
scrutin
amino
acid
sequenc
interact
relev
mhc
molecul
effici
bind
via
proteosom
degrad
system
candid
tumorspecif
peptid
epitop
ctl
identifi
use
avail
comput
algorithm
predict
mhc
bind
affin
specif
peptid
epitop
sequenc
http
bimasdcrtnihgovmolbiohlabind
http
wwwunituebingendeunikxi
subsequ
test
stabil
mhc
molecul
candid
tumorspecif
peptid
vitro
estim
potenti
immunogen
silicoidentifi
antigen
determin
maecker
et
al
immunogen
human
cancer
gene
predict
ctl
peptid
epitop
also
assess
anim
model
use
hla
transgen
mice
butterfield
et
al
provid
even
better
estim
immunotherapi
target
vivo
recent
experi
involv
screen
human
tumor
sampl
ctl
reactiv
identifi
human
gliomaassoci
antigen
epitop
specif
recogn
immun
system
associ
extend
surviv
okano
et
al
ueda
et
al
base
recent
advanc
suggest
cancer
genom
directli
link
tumor
immunotherapi
revers
immunolog
pave
way
design
new
specif
target
brain
tumor
immunotherapi
adopt
transfer
immun
cell
introduct
adopt
patient
either
autolog
allogen
immun
cell
may
may
stimul
vitro
tumor
antigen
mitchel
et
al
sometim
cell
inject
tumor
caviti
maxim
exposur
infus
cell
tumor
cell
strategi
call
system
infus
cytolyt
effector
cell
cultur
vitro
cytokin
activ
attack
tumor
tissu
vivo
approach
clinic
applic
discoveri
cytokin
modul
tcell
growth
surviv
time
possibl
obtain
suffici
number
immun
cell
maintain
cultur
vitro
sensit
period
origin
call
tcell
growth
factor
cytokin
mediat
lymphocyt
activ
stimul
divis
recent
year
abil
adopt
transfer
defin
tumor
antigenspecif
cell
greatli
increas
knowledg
critic
home
marker
cytokin
depend
vivo
traffick
pattern
necessari
target
erad
tumor
brain
preclin
studi
rat
murin
glioma
model
first
demonstr
polyclon
gliomaspecif
cell
could
erad
cn
glioma
baldwin
et
al
kruse
et
al
plautz
et
al
rice
et
al
associ
enhanc
traffick
lymphocyt
brain
hazelrigg
et
al
subsequ
work
demonstr
drain
ln
popul
lymphocyt
isol
also
includ
suppressor
popul
impair
efficaci
adopt
transfer
popul
peng
et
al
remov
popul
enrich
lymphocyt
popul
enhanc
antitumor
activ
plautz
et
al
contrast
recent
studi
adopt
immun
clonal
deriv
lymphocyt
use
case
popul
identifi
cell
central
memori
phenotyp
possess
enhanc
traffick
expans
surviv
klebanoff
et
al
differ
model
may
account
differ
observ
suggest
care
character
cellular
infus
critic
antitumor
activ
cytokin
influenc
prime
tumor
antigenspecif
cell
prior
adopt
transfer
subsequ
alter
home
pattern
surviv
antitumor
activ
adopt
transfer
model
antigenspecif
cell
polar
type
cytokin
profil
use
block
antibodi
nishimura
et
al
cell
show
preferenti
home
intracrani
tumor
probabl
due
high
express
integrin
discuss
enhanc
antitumor
efficaci
sasaki
et
al
work
demonstr
chemokin
tumorderiv
monocyt
chemotact
desbaillet
et
al
suffici
mediat
tropism
tumorspecif
cell
intracrani
tumor
brown
et
al
recent
studi
also
demonstr
tumorspecif
cell
prime
antigen
lead
enhanc
traffick
intracrani
tumor
migrat
cervic
ln
spleen
bone
marrow
prin
et
al
adopt
transfer
set
endogen
host
cytokin
also
import
surviv
effector
function
transfer
cell
host
lymphodeplet
via
whole
bodi
radiat
cytotox
chemotherapi
facilit
homeostat
expans
adopt
transfer
cell
improv
competit
endogen
cytokin
gattinoni
et
al
elimin
endogen
regulatori
cell
chang
et
al
andor
enhanc
intratumor
accumul
transfer
cell
wang
et
al
recent
work
demonstr
tlr
agonist
imiquimod
prin
et
al
inhibitor
fujita
et
al
increas
serum
cytokin
enhanc
antitumor
activ
adopt
transfer
cell
intracrani
tumorbear
mice
studi
collect
suggest
cytokin
microenviron
impos
phenotyp
chang
tumorspecif
cell
alter
vivo
traffick
pattern
function
tropism
tumor
grow
anatom
distinct
compart
discuss
earlier
dc
potent
apc
bodi
due
part
high
express
mhc
class
ii
costimulatori
molecul
secret
cytokin
promot
cell
prime
eg
immun
activ
dc
facilit
engag
effector
mechan
immun
system
ctl
helper
cell
th
well
nk
cell
antibodi
use
dc
cancer
immunotherapi
becam
feasibl
decad
ago
advent
new
techniqu
grow
cell
bone
marrow
precursor
anim
thurner
et
al
monocyt
human
peripher
blood
kiertscher
roth
advantag
prompt
wide
array
preclin
studi
defin
constraint
mechan
dc
prime
tumorspecif
tcell
respons
dcbase
immunotherapi
accommod
mani
differ
form
antigen
chief
among
use
materi
deriv
autolog
tumor
cell
dc
puls
tumorelut
peptid
liau
et
al
apoptoticnecrot
tumor
cell
siesjo
et
al
tumor
lysat
aoki
et
al
ni
et
al
pellegatta
et
al
tumorderiv
rna
insug
et
al
even
glioma
neurospher
pellegatta
et
al
induc
relev
antitumor
immun
tumor
brain
advantag
use
materi
approach
applic
neoplasm
immunogen
tumorspecif
tumorassoci
antigen
unknown
disadvantag
howev
autolog
tumor
extract
may
heterogen
therefor
difficult
character
quantit
also
use
unfraction
tumor
materi
may
lead
rel
low
concentr
effect
immunogen
mixtur
antigen
tumor
peptid
may
conceiv
dilut
rel
nonimmunogen
protein
therebi
lower
immunogen
vaccin
furthermor
risk
induc
immun
selfantigen
may
lead
autoimmun
enceph
real
bigner
et
al
altern
form
antigen
load
dcbase
vaccin
includ
use
defin
peptid
genet
transfect
mors
et
al
riba
demonstr
tumorspecif
mhc
class
irestrict
peptid
puls
onto
dc
use
induc
signific
antitumor
immun
intracrani
tumor
ciesielski
et
al
hatano
et
al
heimberg
et
al
prin
et
al
similarli
viral
transduct
dc
tumor
antigen
broder
et
al
cytokin
kim
et
al
tsugawa
et
al
yamanaka
et
al
andor
fusion
dc
tumor
cell
kjaergaard
et
al
gener
antitumor
immun
translat
clinic
trial
current
dc
recogn
promis
vehicl
activ
immunotherapi
cancer
numer
anim
experi
demonstr
potenti
dcbase
immunotherapi
protect
mice
tumor
format
elimin
establish
tumor
howev
work
shown
dc
vaccin
effect
prime
tumorspecif
tcell
respons
rel
ineffici
boost
respons
jouanneau
et
al
thu
rational
incorpor
dc
vaccin
chemotherapi
adjuv
andor
viral
vector
may
synerg
induc
therapeut
antitumor
immun
becom
clear
preclin
studi
human
trial
enhanc
dc
vaccin
adjuv
requir
gener
antitumor
immun
respons
reproduc
effect
long
last
dc
express
numer
tlr
see
import
host
defens
bacteria
microbi
pathogen
barrat
coffman
barton
medzhitov
pulendran
stimul
tlr
ultim
result
gene
express
profil
lead
product
cytokin
includ
well
type
type
ii
ifn
barton
medzhitov
pulendran
tlr
ligat
dc
induc
matur
signal
upregul
mhc
costimulatori
molecul
express
induc
migrat
ln
induc
express
cytokin
promot
enhanc
tcell
prime
tumor
steinman
banchereau
sinc
commonli
believ
activ
dc
prime
tcell
respons
effect
steinman
banchereau
numer
group
util
adjuv
effect
matur
dc
cancer
immunotherapi
exampl
agonist
imiquimod
could
synerg
peptidepuls
dc
vaccin
paradigm
induc
effect
antitumor
immun
intracrani
tumor
prin
et
al
imiquimod
enhanc
dc
surviv
traffick
ln
also
prime
self
tumor
antigenspecif
cell
prin
et
al
similar
find
report
polyiclc
agonist
zhu
et
al
cpg
agonist
wu
et
al
blockad
immunoinhibitori
molecul
also
gener
antitumor
immun
andor
synerg
activ
vaccin
approach
treatment
cn
tumor
treg
see
recent
shown
accumul
peripher
blood
tumor
mice
grauer
et
al
patient
el
andaloussi
lesniak
fecci
et
al
malign
glioma
associ
degre
malign
immun
compet
el
andaloussi
lesniak
fecci
et
al
heimberg
et
al
learn
et
al
data
suggest
tumorderiv
factor
may
influenc
type
immun
evas
prevent
proper
immun
surveil
tumor
aris
cn
recent
studi
demonstr
blockad
neg
costimulatori
molecul
amelior
chang
tcell
compart
confer
longterm
surviv
intracrani
tumorbear
anim
fecci
et
al
similarli
other
recent
demonstr
function
blockad
treg
vivo
mab
administr
enhanc
antitumor
immun
vaccin
prophylact
set
fecci
et
al
grauer
et
al
howev
studi
highlight
difficulti
treg
deplet
sinc
mab
use
therein
also
bind
inhibit
activ
cell
complet
remov
benefici
effect
activ
vaccin
immunotherapi
establish
intracrani
tumorbear
mice
curtin
et
al
studi
highlight
import
tcell
compart
cn
tumor
immun
new
methodolog
explor
function
revers
treg
influenc
combin
antitumor
vaccin
strategi
studi
cancer
vaccin
use
irradi
whole
tumor
cell
modifi
cytokin
gene
review
okada
pollack
viral
vector
review
curtin
et
al
even
live
attenu
bacteri
vector
liau
et
al
prin
et
al
gener
antitumor
immun
pioneer
cytokin
gene
therapi
studi
perform
decad
ago
demonstr
cytokinesecret
tumor
cell
could
induc
antitumor
immun
cn
tumor
model
cytokinegen
therapi
studi
abl
demonstr
efficaci
antitumor
immun
intracrani
glioma
induct
gmcsf
mmcsf
glick
et
al
dey
et
al
cytokinesecret
tumor
reveal
multipl
facet
cellular
immun
respons
could
mobil
induc
antitumor
immun
group
util
intracrani
inject
viral
vector
encod
cytokin
andor
condit
cytotox
hsvtk
ali
et
al
curtin
et
al
see
also
chapter
live
bacteria
andor
virus
may
also
serv
basi
activ
immunotherapi
brain
tumor
chabalgo
et
al
viralbacteri
infect
result
tissu
damag
also
provid
appropri
danger
signal
matzing
attract
profession
apc
necessari
adequ
antigen
present
ctlmediat
immun
induc
use
live
attenu
bacteri
viral
vector
stimul
innat
immun
system
simultan
deliv
antigen
chabalgo
et
al
instanc
listeria
monocytogen
lm
facult
gramposit
intracellular
bacterium
abl
enter
host
cell
escap
endocyt
vesicl
multipli
within
cytoplasm
spread
directli
cell
cell
without
encount
extracellular
milieu
antigen
express
lm
access
mhc
class
class
ii
process
pathway
present
cell
addit
lm
shown
stimul
tlr
barton
medzhitov
surfac
apc
activ
intern
pattern
recognit
molecul
may
contribut
immunostimulatori
action
ulevitch
publish
studi
demonstr
immun
attenu
recombin
listeria
monocytogen
rlm
express
lymphocyt
choriomening
viru
nucleoprotein
lcmvnp
led
reject
glioma
express
heterolog
np
antigen
liau
et
al
interestingli
anim
clear
tumor
subsequ
immun
rechalleng
subcutan
intracrani
glioma
cell
express
np
suggest
epitop
spread
occur
phenomenon
wherebi
cell
recogn
endogen
glioma
epitop
along
target
antigen
liau
et
al
given
heterogen
human
brain
tumor
possibl
immun
escap
exploit
process
epitop
spread
valuabl
clinic
context
futur
tumor
vaccin
design
studi
reveal
complex
multipl
mechan
antitumor
immun
gener
major
previou
clinic
adopt
immunotherapi
trial
brain
tumor
employ
lymphokineactiv
killer
lak
mitogenactiv
killer
cell
lak
cell
peripher
blood
lymphocyt
function
defin
abil
lyse
nkresist
tumor
target
vitro
follow
stimul
andor
mitogen
lak
cell
implant
resect
caviti
surgeri
dillman
et
al
hay
et
al
merchant
et
al
b
sporad
clinic
respons
observ
howev
lak
cell
therapi
nonspecif
cell
stimul
vitro
gliomaspecif
antigen
limit
lak
cell
adopt
transfer
erad
tumor
cell
clinic
trial
may
due
inher
nonspecif
fact
cell
migrat
effici
tumor
site
andor
induct
diffus
cerebr
edema
cytokin
one
refin
previou
adopt
transfer
approach
stimul
lymphocyt
vivo
autolog
tumor
cell
gener
mhc
class
irestrict
ctl
expand
vitro
reinfus
patient
kruse
et
al
merchant
et
al
theori
antigenstimul
ctl
would
specif
lak
cell
clinic
trial
use
adopt
transfer
activ
ctl
produc
somewhat
encourag
initi
result
kruse
et
al
plautz
et
al
wood
et
al
howev
pilot
phase
trial
design
primarili
demonstr
feasibl
safeti
definit
evalu
efficaci
requir
studi
often
pilot
trial
adopt
immunotherapi
suggest
efficaci
ishikawa
et
al
quattrocchi
et
al
follow
phase
ii
iii
larger
trial
design
show
true
improv
surviv
adopt
transfer
studi
melanoma
particularli
encourag
current
treat
patient
object
clinic
respons
recist
criteria
dudley
et
al
howev
abil
clone
expand
highaffin
tumorinfiltr
lymphocyt
current
restrict
center
newer
option
may
becom
feasibl
futur
gliomaspecif
tcr
clone
use
genet
engin
specif
confer
tumor
recognit
normal
lymphocyt
morgan
et
al
altern
use
bispecif
antibodi
potenti
engag
ctl
patient
lysi
cancer
cell
may
therapeut
potenti
treatment
malign
diseas
contrari
antibodybas
approach
call
inject
massiv
dose
purifi
antibodi
recent
studi
shown
tumor
regress
nonhodgkin
lymphoma
patient
treat
patient
low
dose
recombin
bispecif
antibodi
blinatumomab
render
cancer
cell
sensit
almost
ctl
may
encount
bargou
et
al
conceiv
bispecif
singlechain
antibodi
one
variabl
region
recogn
antigen
tumor
cell
variabl
region
bind
may
engin
solid
tumor
malign
glioma
overal
appear
adopt
immunotherapi
may
offer
certain
advantag
activ
vaccin
strategi
provid
cell
expand
absenc
tumorderiv
solubl
factor
ctl
grown
extrem
larg
number
suffici
infus
wang
et
al
summari
recent
publish
clinic
trial
adopt
cellular
immunotherapi
malign
glioma
present
tabl
approach
combin
adopt
transfer
antigenpuls
dc
tumor
vaccin
malign
glioma
patient
current
activ
investig
sever
differ
center
around
world
caruso
et
al
de
vleeschouw
et
al
kikuchi
et
al
liau
et
al
yamanaka
et
al
yu
et
al
yu
et
al
strategi
involv
ex
vivo
exposur
patient
dc
tumor
antigen
follow
vivo
infus
stimul
endogen
immun
respons
liau
et
al
prin
et
al
theori
behind
therapeut
strategi
base
upon
evid
tumor
cell
poor
apc
adequ
stimul
endogen
profession
apc
lack
immun
activ
may
affect
cell
also
helper
cell
th
requir
antigen
present
associ
mhc
class
ii
unless
tumor
antigen
secret
solubl
protein
process
profession
apc
ctl
respons
handicap
lack
critic
th
function
cytokin
secret
full
dc
activ
solubl
antigen
may
releas
tumor
cell
later
stage
develop
necrot
area
time
tumor
may
past
threshold
growth
imped
immun
activ
circumv
investig
use
ex
vivo
cytokin
stimul
dc
antigen
exposur
autolog
dc
autolog
tumor
lysat
tumor
peptid
tumor
cell
fusion
tabl
recent
phase
clinic
trial
followup
patient
newli
diagnos
n
recurr
n
glioblastoma
enrol
patient
receiv
standard
care
includ
surgeri
follow
extern
beam
radiat
therapi
glioma
cell
dissoci
tumor
specimen
cultur
vitro
approxim
week
cultur
mhcbound
tumor
peptid
elut
surfac
tumor
cell
use
acidelut
protocol
liau
et
al
patient
autolog
dc
harvest
peripher
blood
mononuclear
cell
subsequ
load
autolog
acidelut
tumor
peptid
patient
receiv
three
intraderm
inject
peptidepuls
dc
interv
although
phase
studi
power
detect
clinic
efficaci
provid
evid
feasibl
safeti
vivo
bioactiv
autolog
peptidepuls
dc
patient
glioblastoma
similar
studi
kikuchi
et
al
liau
et
al
yajima
et
al
yamanaka
et
al
yu
et
al
although
admittedli
select
popul
patient
prolong
surviv
time
signific
immunolog
respons
observ
patient
support
possibl
immunerel
effect
tumor
control
recent
studi
correl
quantit
tcell
immun
respons
measur
enhanc
clinic
time
tumor
progress
ttp
surviv
wheeler
et
al
proof
clinic
benefit
dcbase
vaccin
remain
establish
futur
multicent
phase
ii
clinic
trial
malign
glioma
patient
current
underway
follow
conclus
drawn
dcbase
clinic
trial
data
date
first
dc
therapi
appear
rel
safe
well
toler
part
seriou
side
effect
observ
trial
second
mani
trial
report
induct
cellular
immun
humor
immun
vaccin
compon
importantli
trial
report
completeparti
respons
rate
prolong
surviv
suggest
dcbase
immunotherapi
significantli
impact
diseasefre
overal
surviv
true
benefit
therapi
still
need
assess
rigor
control
random
trial
underway
salmonella
typhimurium
gramneg
enterobacterium
caus
typhoid
fever
motil
bacteria
anaerob
metabol
therefor
thrive
hypox
environ
occur
tumor
salmonella
typhimurium
attenu
genet
modifi
puri
msbb
gene
respons
virul
innat
immun
recognit
respect
found
specif
target
local
transplant
murin
tumor
partial
inhibit
tumor
growth
vivo
clairmont
et
al
rosenberg
et
al
preclin
result
led
phase
clinic
trial
intraven
administr
attenu
salmonella
typhimurium
patient
metastat
melanoma
rosenberg
et
al
clinic
studi
show
strain
salmonella
typhimurium
could
safe
administ
patient
tumor
colon
salmonella
observ
highest
toler
dose
howev
antitumor
effect
seen
toso
et
al
viral
vaccin
also
investig
treatment
malign
glioma
schneider
et
al
recent
newcastl
diseas
viru
vaccin
use
four
patient
advanc
highgrad
glioma
purport
surviv
time
year
csatari
et
al
similar
expand
studi
vaccin
prepar
patient
tumor
cell
cultur
infect
newcastl
diseas
viru
use
follow
gammairradi
nonrandom
studi
vaccin
patient
compar
nonvaccin
control
surviv
rate
vaccin
patient
compar
control
p
viralbas
vaccin
appear
feasibl
safe
improv
prognosi
vaccin
patient
substanti
observ
antitumor
immun
respons
steiner
et
al
immunebas
therapi
outlin
util
principl
basic
immunolog
find
strategi
hope
bring
us
closer
goal
kill
residu
microscop
tumor
cell
lead
inevit
recurr
malign
glioma
major
improv
understand
glioma
molecular
biolog
tumor
immunolog
translat
innov
clinic
trial
provid
new
hope
patient
devast
diseas
see
tabl
challeng
work
done
today
take
basic
immunolog
clinic
realm
date
clinic
trial
immunotherapi
cn
glioma
yet
demonstr
object
proof
clinic
efficaci
rigor
multicent
phase
ii
iii
studi
nevertheless
trial
pursu
encourag
result
mani
phase
studi
salgal
liau
futur
test
field
continu
abil
design
effect
target
immun
therapi
matur
hope
yield
increas
therapeut
success
mind
prioriti
area
research
scientif
investig
appear
critic
time
involv
develop
techniqu
new
antigen
identif
base
readili
avail
sourc
inform
gene
gene
product
abnorm
express
primari
tumor
cell
ryu
et
al
examin
produc
immunogen
antigen
andersen
et
al
character
cn
system
immun
respons
patient
brain
tumor
develop
immunotherapi
optim
particular
brain
effici
home
effector
cell
accept
level
local
inflamm
consid
problem
challeng
pose
patient
tumor
heterogen
note
target
treatment
modal
brain
tumor
immunotherapi
trial
might
realiz
signific
potenti
clinic
efficaci
given
appropri
subgroup
patient
andor
administ
combin
therapi
current
experi
cancer
treatment
appear
simultan
target
sever
compon
essenti
neoplast
process
provid
maxim
chanc
tumor
control
therefor
therapi
base
immunoenhanc
cancer
vaccin
could
combin
tradit
surgeri
radiat
chemotherapi
along
molecularli
target
biolog
agent
integr
treatment
strategi
may
prove
low
toxic
synergist
addit
combin
use
convent
treatment
within
context
clinic
trial
immunotherapi
allow
evalu
efficaci
yet
retain
ethic
requir
human
investig
next
decad
concept
stimul
patient
natur
immun
produc
antitumor
respons
may
lead
approach
custom
immunotherapi
salgal
patient
malign
glioma
person
immunotherapeut
may
potenti
solut
deal
import
observ
patient
tumor
hetereogen
howev
still
signific
obstacl
develop
highli
patientselect
treatment
patient
accrual
clinic
trial
slower
potenti
market
approv
product
lower
develop
time
clinic
applic
prolong
furthermor
signific
manufactur
challeng
face
clinic
develop
mani
immunotherapeut
especi
regard
patientspecif
vaccin
arguabl
greatest
technic
financi
hurdl
get
type
treatment
largescal
pivot
trial
socal
gmplevel
facil
mani
academ
campus
meet
stricter
regul
fda
nonpilot
studi
clinic
develop
cellular
therapi
biolog
agent
brain
tumor
requir
partnership
intern
academ
medic
center
govern
agenc
biotechnolog
compani
order
overcom
manufactur
challeng
current
imped
largescal
multicent
phase
iii
clinic
trial
point
alreadi
plethora
smallscal
phase
iii
brain
tumor
immunotherapi
trial
still
await
confirm
clinic
efficaci
order
obtain
meaning
biolog
clinic
data
complic
trial
custom
immunotherapi
select
patient
group
larger
multiinstitut
studi
need
perform
structur
collabor
academ
commun
medic
center
biotechnolog
industri
patient
advocaci
group
current
immunotherapi
cautious
deliber
make
way
patient
bedsid
adjunct
standard
modal
surgeri
radiotherapi
chemotherapi
number
clinic
trial
evalu
immunotherapeut
strategi
still
limit
current
advanc
highthroughput
product
clinicalgrad
cellularbiolog
therapeut
moleculargenet
target
identif
hope
spur
futur
clinic
develop
